Clinical Testing News and Research

RSS

CIRM grant funds new stem cell therapy to heal hearts

A new $6.9 million grant from the California Institute for Regenerative Medicine (CIRM) will support preclinical development of an investigational cell therapy for the heart created by USC Stem Cell scientists.

5 Nov 2026

UCLA advances CRISPR gene-editing therapy for sickle cell disease

A UCLA-led team has described how they advanced an experimental CRISPR approach for sickle cell disease into a blood stem cell therapy that can be manufactured at the scale and quality required for a clinical trial.

4 Nov 2026

New host target identified to block hepatitis E virus

Hepatitis E virus (HEV) is a major cause of acute viral hepatitis, yet antiviral treatment remains largely limited to the off-label use of ribavirin. Ribavirin can cause substantial toxicity, is contraindicated during pregnancy and does not reliably benefit every patient.

29 Oct 2026

Study identifies potential new ways to treat the most common type of bowel cancer

Major new research published today identifies potential new ways to treat the most common type of bowel cancer in Ireland.

23 Oct 2026

First patient dosed in Phase 1 clinical trial of new cancer drug

On August 18, 2026, in Japan, the Department of New Experimental Therapeutics and Early-Phase 1 Drug Development Service at Kansai Medical University Hospital, led by Professor Toshio SHIMIZU, administered DS1025 to the first patient worldwide as part of a global, multicenter First-in-Human Phase 1 clinical trial sponsored by Daiichi Sankyo.

19 Oct 2026

Investigational knee injection targets cartilage loss in osteoarthritis patients

Keck Medicine of USC has launched a clinical trial testing the safety and tolerability of a new investigational treatment and its potential effects on preventing cartilage deterioration in people with knee osteoarthritis, the most common form of the disease.

14 Oct 2026

New modeling reveals high societal value of early Alzheimer's care

New treatments that can slow the progression of Alzheimer's disease could provide significant lifetime benefits to patients and society, with even greater benefits when initiated earlier, according to new research from the USC Schaeffer Center for Health Policy & Economics.

7 Oct 2026

UCLA researcher wins the 2026 Albany Prize for revolutionary cancer therapy discoveries

Dr. Dennis Slamon, a pioneering oncologist and researcher at the UCLA Health Jonsson Comprehensive Cancer Center, has been awarded the 2026 Albany Prize for discoveries that transformed the understanding and treatment of cancer.

6 Oct 2026

Experimental cancer drug works differently than researchers originally thought

A cancer drug currently being tested in patients may have entered clinical trials based on an incorrect understanding of how it works, according to a new study led by the University of Sydney in collaboration with Goethe University, Oxford University and the Institute of Cancer Research, London.

6 Oct 2026

Battery-free smart shoe could help monitor movement disorders

Rutgers engineers have developed a smart shoe that automatically analyzes how a person walks, a technology that someday could help monitor people with Parkinson's disease, spinal cord injuries, traumatic brain injuries, and other movement disorders.

29 Sep 2026

Screening approved medicines reveals potential treatments for preterm labor

Shajila Siricilla, PhD, Assistant Professor of Pediatrics, and Jennifer Herington, PhD, Associate Professor of Pediatrics, led a team that systematically screened 1,191 FDA-approved drugs and found that several candidates met criteria supporting further evaluation as potential treatments for preterm labor.

23 Sep 2026

City of Hope develops adaptive plug-and-play CAR T technology to attack tumors

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the country, have developed a new "plug-and-play" technology that adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer.

22 Sep 2026

Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101

Galimedix Therapeutics, Inc., a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced the establishment of a dedicated Alzheimer's Disease Scientific Advisory Board (SAB).

From Galimedix Therapeutics, INC. 22 Sep 2026

Quotient Sciences proprietary AI-enhanced solution optimizes formulation in clinical study

Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), today reported interim results from a clinical study in which a proprietary artificial intelligence (AI) algorithm selected modified-release formulation compositions and doses during the trial.

From Quotient Sciences 18 Sep 2026

Silica and dust mites combine to worsen asthma inflammation

Inflammation associated with asthma and other allergic airway diseases can be significantly worsened by exposure to both house dust mite allergens and crystalline silica, according to a new study published in the journal Allergy.

15 Sep 2026

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard treatment options.

11 Sep 2026

Evaluating new approaches for rare disease research

Marcel Nelen discusses his team’s early evaluation of a new workflow for rare disease genomics.

From Illumina, Inc. 10 Sep 2026

Protein-based MRI agent detects tiny lung cancer metastases

A multi-institutional research team led by Georgia State University Regents' Professor Emerita of Biochemistry and Biophysical Chemistry Jenny J. Yang has developed a new class of protein-based MRI contrast agent that detects invasive lung cancer and metastatic disease at earlier stages than conventional imaging approaches.

9 Sep 2026

New AI model forecasts glucose changes in type 1 diabetes patients

Diabetes is one of the most common chronic diseases, affecting around 66 million adults in Europe - a figure projected to rise to more than 72 million by 2050.

9 Sep 2026

New dual-drug strategy blocks triple-negative breast cancer growth

Triple-negative breast cancer (TNBC) has a frustrating ability to adapt. Although this aggressive form of breast cancer can initially respond well to chemotherapy, cancer cells often find ways to survive, allowing the disease to return and become resistant to treatment.

31 Aug 2026